Name Duk-Woo Park
Country Korea (South)
Job Interventional Cardiologist

Other content(s) by This

  1. Impact of DES on Diabetes Mellitus in Long Coronary Lesion
  2. Meta-Analysis of 3,900 Patients with Left Main Disease Intervention (BMS vs DES vs CABG)
  3. VH AMC Clinical Experience
  4. Wrapping Up Current Clinical Trials and Future Study Program
  5. Use of VH-Findings as Surrogate Marker for Anti-Atherosclerotic Drug
  6. DES vs. CABG for Multivessel Disease: Same or Different Interpretation from Registry to RCT
  7. Seeing Is Believing. IVUS Is A Mandatory in All Patients!
  8. Alternative and Next Antiplatelet Therapy Beyond ADP Blocker
  9. Early DES - What Did We Learn - Updates from the ZEST Trial
  10. AMC Experience of the Intervention for the Structural Heart Disease
  11. Long-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease: 10-Year Results of Bare-Metal Stents and 5-Year Results of Drug-Eluting Stents From the ASAN–MAIN (ASAN Medical Center–Left MAIN Revascularization) Registry
  12. Use of a Point-of-Care Platelet Function Assay to Improve the Prediction of Atherothrombotic Events after DES Implantation: ASAN-VerifyNow Registry
  13. Where to Go? - Comparative Analysis: BMS, DES vs. BVS / - The Next Step: BVS in Challenging Lesions
  14. Can Different DES Make a Different Outcome?
  15. RDN; Indications & Evidence and Future
  16. Shifting the Paradigm for Lipid Management: Pathways in Achieving Improved ASCVD Outcomes
  17. Can BVS Replace the Metal Stent?: Current Status and Future Perspective
  18. Comparative Outcomes of New-Generation DES: IRIS-DES
  19. Balloon-Expandable SAPIEN 3 Valve
  20. TAVR Will Be a Standard Treatment for All Patients with Aortic Stenosis
  21. BVS: They Will Replace Metallic DES?
  22. Effect of Statin Therapy on Cardiovascular Outcome in Dyslipidemic Patients with CKD
  23. DES Thrombosis and Restenosis: Still Problematic in Current Real-World with Updated DES
  24. BRS in Left Main PCI: Clinical Data and Experience
  25. Bifurcation PCI Summary; Technique or Concept?
  26. How Much Promising BRS in Real-Practice PCI?; Updated Real-World Experience and Registry Data
  27. Growing Importance of Evidence in the Management of High CV Risk Patients
  28. SYNERGY : Latest Experience from Korea
  29. Future in Transcatheter Heart Valve Treatment
  30. Bifurcation PCI 2019: What Are Novel Changes for Technique or Concept?
  31. Generalizability of EXCEL and NOBLE; Comparison with IRIS-MAIN Registry
  32. Contemporary Bifurcation PCI; How Advance over Time?
  33. Long-Term Durability Issue of TAVR; Uncertainty or Would Be OK
  34. Permanent Pacemaker and Para-valvular Leakage: How to Avoid?
  35. How Do I Choose Sapien 3, Evolut R or Lotus in My Practice?
  36. [Taped Case] TAVR with Sapien
  37. Mainstream of TAVR: Minimalist Approach
  38. Trends and Outcomes of Non-LM and LM Bifurcation PCI
  39. All Contemporary DES Comparison; Data from Real-World Registry (IRIS-DES)
  40. Optimal Antithrombotic Therapy and Ongoing Clinical Trials
  41. CTEPH; Diagnosis & Treatment
  42. Standard vs. Minimalist TAVR: When and How to Change?
  43. TAVR - Moving to Lower Risk: STS or Age Per Se?
  44. Keynote Lecture on Bifurcation PCI: Expert\'s Concept and Technique
  45. Heavily Calcified Lesion: Rotational Atherectomy and Others
  46. Top 10 Tips on Bifurcation PCI
  47. Highlighting 20 years of CV Protection with Lipitor
  48. OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients
  49. Valve Thrombosis, Durability and Ongoing Antithrombotic Trials for TAVR
  50. EBC-MAIN Like Analysis Using the Largest Real-World Left Main Database
  51. Comparative Outcomes of Contemporary DES in Real-World: Is There Difference?
  52. Clinical Impact of Periprocedural Myocardial Injury After TAVR
  53. TAVR in Asia: Current Challenges and Future Direction
  54. Metallic DES Are All Equivalent!
  55. Ture Distal Left Main PCI (Medina 1,1,1 or 1,0,1) Contemporary Strategy: Provisional vs. Complex
  56. Time to Consider Different P2Y12 Strategy for Complex PCI/CHIP Patients: From OPTIMA to TAILORED-PCI Trial
  57. Minimalist TAVR with Edwards SAPIEN 3 Valve
  58. Integrated Use of FFR and IVUS in Non-LM Bifurcation PCI
  59. Severe Coronary Calcification: Predictors, Managing Strategy, and Outcomes
  60. PCI in Post-TAVR Patients: Beyond the Barrier
  61. How To Do Successful Registry Studies?
  62. East-Asian Paradox: How to Optimize P2Y12 Inhibitors for Asians?
  63. LM Bifurcation
  64. Anticoagulation for TAVR: GALILEO, and Yet It Moves.
  65. 10-Year Follow-Up of MAIN-COMPARE Registry and Substudies
  66. OCT Versus IVUS for Guiding PCI: Current Evidences and Ongoing OCTIVUS Trial
  67. Optimal Antithrombotics After TAVR: Ongoing Trials
  68. Impact of Severe Coronary Artery Calcification on PCI Outcomes
  69. Bifurcation PCI: Data, Evidence, and Guidelines
  70. Current Status of TAVR in Korea and US: TP-TAVR Registry
  71. Optimal Antithrombotics After TAVR
  72. Integrated Use of Imaging and Physiology in Left Main PCI
  73. Antithrombotic and Antiplatelet Choice in Complex PCI
  74. [Master\'s Keynote Lecture] Hand Down a Secret of Left Main PCI